Myriad Genetics (NASDAQ:MYGN) Updates FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.070-0.110 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $863.0 million.

Myriad Genetics Price Performance

Shares of MYGN opened at $10.34 on Thursday. The company has a market cap of $941.30 million, a price-to-earnings ratio of -7.95 and a beta of 1.88. Myriad Genetics has a twelve month low of $9.76 and a twelve month high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $13.15 and a two-hundred day moving average of $18.66.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. As a group, analysts predict that Myriad Genetics will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. StockNews.com downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Saturday, March 1st. Leerink Partners downgraded shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Bank of America decreased their target price on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a research report on Monday. Craig Hallum assumed coverage on shares of Myriad Genetics in a research report on Wednesday, February 12th. They set a “buy” rating and a $29.00 target price for the company. Finally, Morgan Stanley cut their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $21.82.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.